|
| EDITORIAL |
|
| Year : 2010 | Volume
: 2
| Issue : 2 | Page : 61 |
 |
|
The new face of PVRI review
S Harikrishnan
Editor in Chief, PVRI Review,Fellow, Pulmonary Vascular Research Institute, Co-leader, PVRI Publication Taskforce,
| Date of Web Publication | 16-Aug-2010 |
Correspondence Address:
S Harikrishnan
Editor in Chief, PVRI Review,Fellow, Pulmonary Vascular Research Institute, Co-leader, PVRI Publication Taskforce
 DOI: 10.4103/0974-6013.68483
How to cite this article:
Harikrishnan S. The new face of PVRI review. PVRI Review 2010;2:61 |
Following the decisions in the last AGM held at Lisbon in January 2010, PVRI Review is getting a new face. Since PVRI is coming out with its peer-reviewed journal Pulmonary Circulation, the role of PVRI Review had to be redefined. It will be the official newsletter of PVRI, publishing all the activities going on in different PVRI regions. It will publish reports on the activities of the regional PVRI task forces and on various meetings held under the auspices of PVRI.
In addition to its function as a newsletter, it will also publish view points, case studies, commentaries on interesting articles published in major journals, and compilation of all articles published elswhere on PH (Journal Scan). PVRI Review will become a forum to express the personal viewpoints and opinion as well as observations in the field of pulmonary vascular diseases. The articles will be not representing the views of editorial board of PVRI or PVRI, but it will be sole opinion of the authors. Also, it was decided to have PVRI Review published thrice a year, in July, October and January.
In this issue of PVRI Review, we have a special report on the very successful inaugural meeting conducted by the sub-Saharan region task force. Professor Karen Sliwa has written an introduction and also an overview of the meeting. Following this, the articles written by the presenters at the meeting are included.
Bernard Thιbaud, in a review article, observes that the old notion that the development of blood vessels in the lung passively follows that of the airways is challenged with new evidences. We have new data to show that lung blood vessels actively promote alveolar growth during development and contribute to the maintenance of alveolar structures throughout postnatal life. These observations are relevant in pulmonary hypertension which is characterized by arrested alveolar growth/loss of alveoli. This short review summarizes the recently recognized role of angiogenic growth factors during normal alveolar development, injury and repair.
Antonio Augusto Lopes and Andrι Cogo Dalmaschio have written an excellent review article on Eisenmenger syndrome. Eisenmenger syndrome (reversed right-to-left shunting caused by heightened pulmonary vascular resistance) is not uncommon in the developing world, where the corrective intervention for left-to-right shunt lesions is usually not undertaken at the right time. Eisenmenger syndrome is a multisystemic disorder associated with progressive right heart failure and hypoxemia. The authors conclude that even in the era of the "new drugs" for treatment of pulmonary hypertension, general therapeutic measures remain central in the management of patients with Eisenmenger syndrome.
Brain natriuretic peptide (BNP) is a marker which is utilized in the diagnosis and assessing the prognosis in patients with ventricular failure. Brian Casserly and James R. Klinger review the utility of BNP in the management of patients with PH. They conclude that BNP may be a useful marker for right ventricular dysfunction and shows great promise in estimating the efficacy of therapy in patients with PAH.
You all may be aware about the webinars which are aired by pahforum.com, the webcasts site for the PVRI. We are planning to transcribe the webcasts and publish in our journal. The first of its kind is done by Serge Adenot et al. on pulmonary vascular diseases and COPD. We are publishing this transcription of the webinar along with three case reports on the same topic by Ari Chaouat et al. The combination of these two looks very informative and interesting.
The use of CEC and/or CPC counts as surrogate markers of endothelial status has been investigated in various pathological conditions including pulmonary arterial hypertension (PAH). Swapna Menon in her usual column - Commentary - has reviewed an article by Smadja et al. on the patterns of CEC in PH. She mentions that the current study corroborates observations on CEC count in PAH, i.e. the CEC count appears to be a more reliable marker in PH, with increase in numbers associated with severe disease.
Dear readers, we, in the editorial board, request you to send your suggestions and comments about PVRI Review. Please send your contributions which will suit the new face of PVRI Review.
|
Search Pubmed for